Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 5, 2014, Pages 357-365

  Kong, Qian ^a   Li, Ping ^a   Tian, Qiong ^a   Ha, Min Wen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

ALLELE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL;

EID: 84899860729     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0506     Document Type: Article

References (25)

1. Bond GL, Hu W, Bond EE, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602
2. Camus S, Menendez S, Fernandes K, et al. (2012) The p53 isoforms are differentially modified by MDM2. Cell Cycle 11:1646-1655
3. Chien WP, Wong RH, Cheng YW, et al. (2010) Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol 17: 1194-1202
4. Dong J, Ren B, Hu Z, et al. (2011) MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog 50:433-438
5. Ettinger DS, Akerley W, Bepler G, et al. (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801
6. Han JY, Lee GK, Jang DH, et al. (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113:799-807
7. Heist RS, Zhou W, Chirieac LR, et al. (2007) MDM2 polymorphism, survival, and histology in early-stage non-smallcell lung cancer. J Clin Oncol 25:2243-2247
8. Liang H, Atkins H, Abdel-Fattah R, et al. (2004) Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 338:217-223
9. Lind H, Zienolddiny S, Ekstrom PO, et al. (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119:718-721
10. Liu G, Wheatley-Price P, Zhou W, et al. (2008) Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer 122:915-918
11. Liu L, Wu C, Wang Y, et al. (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6:1793-1800
12. Michaelis M, Rothweiler F, Barth S, et al. (2011) Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drugresistant cancer cells. Cell Death Dis 2:e243
13. Molina JR, Yang P, Cassivi SD, et al. (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594
14. Peters JL, Sutton AJ, Jones DR, et al. (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676-680
15. Rapp E, Pater JL, Willan A, et al. (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641
16. Reifenberger G, Reifenberger J, Ichimura K, et al. (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299-4303
17. Ryan KM, Phillips AC, Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13:332-337
18. Shi D, Gu W (2012) Dual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer 3:240-248
19. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
20. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605
21. Wade M, Wong ET, Tang M, et al. (2006) HDMX modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281:33036-33044
22. Wang SP, Wang WL, Chang YL, et al. (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11:694-704
23. Wang YC, Lin RK, Tan YH, et al. (2005) Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 23:154-164
24. Zhuo W, Zhang L, Zhu B, et al. (2012) Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One 7:e41546
25. Zintzaras E, Ioannidis JP (2005) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21: 3672-3673.